AI Article Synopsis
- The review by Chen et al. aimed to assess how accurately blood-based biomarkers can detect Alzheimer's disease and amnestic mild cognitive impairment.
- However, the authors identified significant methodological flaws in the study, such as lack of a thorough literature search, ignoring negative results, and incorrect data input.
- Due to these issues, the conclusion that blood-based biomarkers are reliable for diagnosing Alzheimer's disease is questionable and needs reevaluation.
Article Abstract
We read with interest the review by Chen et al. They intended to examine the diagnostic accuracy of blood-based biomarkers for detecting Alzheimer's disease and amnestic mild cognitive impairment. We believe that there were substantial methodological flaws in their meta-analysis. These methodological flaws included no comprehensive literature search details, neglect of the negative result research, no prespecified cut-off values, erroneous data input in their meta-analysis, and the issue of prevalence determined by the included studies. These factors potentially contributed to overestimation of the discriminative accuracy of blood-based biomarkers. Subsequently, the conclusion that blood-based biomarkers are effective tools for detecting Alzheimer's disease is debatable without correction of these methodological flaws and providing robust and trustworthy estimates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arr.2023.101938 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!